#therapies

Celltrion Group announced today that the European Commission (EC) has approved Regkirona (regdanvimab, CT-P59), one of ...

Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for ...

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a ...

Smoking, obesity, and high blood pressure can cause Renal Cell Carcinoma (RCC), a type of kidney cancer, a specialist ...

RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of ...

The sharp spike in COVID-19 cases in Indonesia is most likely caused by the highly contagious delta variant, Chairman ...

The Health Ministry on Wednesday afternoon flagged a shortage in stocks of three types of therapeutic drugs used in the ...

infected animals was confirmed with a clinical dosage of regdanvimab (CT-P59)1 Incheon, South Korea--(Antara/Business ...

Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed ...

Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early ...

Smiths Medical, a global medical device leader, today announced it has formed an exclusive partnership with Ivenix, ...

RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today ...

Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and ...

The Indonesian Ministry of Health conducted a phase one clinical trial of the mesenchymal stem cell (MSC) therapy to ...

- LintonPharm Co. Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T-cell ...